---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071551"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:11:08.249189+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243

## Summary
- PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.
- Preclinical data shows durable functional improvement in a humanized DMD mouse model over 9 months with restored dystrophin expression.
- Precision targets to file IND/CTA for PBGENE-DMD in 2025, with clinical data expected in 2026.
- Company pauses development of PBGENE-3243 (m.3243 mitochondrial disease) to prioritize PBGENE-DMD and HBV; cash runway sufficient for both through Phase 1.
- PBGENE-DMD preclinical data presented at ASGCT Annual Meeting on May 14, 2025; webcast held May 15.

## SEC filing metadata
- accession: 0000950170-25-071551
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/0000950170-25-071551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017025071551/dtil-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071551
- JSON: https://secwatch.observer/filing/0000950170-25-071551.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.